Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

451443

registered interest
date	09/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Aspartame
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, in which countries aspartame has been banned; and for what reason each such ban has been enacted.
tabling member constituency	Caithness, Sutherland and Easter Ross
tabling member printed	Dr Paul Monaghan
uin	26682
answer	answer is ministerial correction date of answer 15/02/2016 answer text <p>We are advised by the Food Standards Agency (FSA) that aspartame is permitted in all European Union Member States. It is also permitted in those countries aligned to EU legislation participating in the European Economic Area and European Free Trade Association.</p><p> </p><p>Aspartame has also been evaluated for safety by The Joint FAO/WHO Expert Committee on Food Additives and provisions for its use are included in the international Codex Alimentarius General Standard on Food Additives.</p><p> </p><p>Whilst the FSA is not aware of any countries where aspartame is banned, it is possible there are countries which do not have legislation regulating the use of aspartame or other food additives.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 15/02/2016 09:40:31 answering member 3918 label Biography information for Jane Ellison
tabling member	4383 label Biography information for Dr Paul Monaghan

451448

registered interest
date	09/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Obesity
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to measure the effectiveness of his Department's work to tackle obesity.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	26382
answer	answer is ministerial correction date of answer 15/02/2016 answer text <p>We will be setting out a comprehensive new strategy to tackle childhood obesity in due course.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 15/02/2016 09:46:57 answering member 3918 label Biography information for Jane Ellison
tabling member	1409 label Biography information for Mr Gregory Campbell

451471

registered interest
date	09/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Muscular Dystrophy: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent progress has been made on access to Translarna in discussions between NICE, NHS England and the relevant pharmaceutical company.
tabling member constituency	Leeds North West
tabling member printed	Greg Mulholland
uin	26414
answer	answer is ministerial correction date of answer 12/02/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently evaluating Translarna (ataluren) for the treatment of Duchenne muscular dystrophy through its highly specialised technology programme. The publication date for NICE’s final guidance is to be confirmed.</p><p> </p><p>NHS England has advised that it is in constructive discussions with the pharmaceutical company about the development of a managed access agreement for Translarna and a progress update will be given at the next NICE Evaluation Committee meeting on 17 February 2016.</p><p> </p><p>In the absence of guidance from NICE, it is for commissioners to make decisions on whether to fund medicines based on an assessment of the available evidence.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 26415 question first answered 12/02/2016 16:21:56 answering member 4020 label Biography information for George Freeman
tabling member	1540 label Biography information for Greg Mulholland

451472

registered interest
date	09/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Muscular Dystrophy: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he plans to announce a decision on access to Translarna after the NICE Highly Specialised Technology Committee meeting on 17 February 2016.
tabling member constituency	Leeds North West
tabling member printed	Greg Mulholland
uin	26415
answer	answer is ministerial correction date of answer 12/02/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently evaluating Translarna (ataluren) for the treatment of Duchenne muscular dystrophy through its highly specialised technology programme. The publication date for NICE’s final guidance is to be confirmed.</p><p> </p><p>NHS England has advised that it is in constructive discussions with the pharmaceutical company about the development of a managed access agreement for Translarna and a progress update will be given at the next NICE Evaluation Committee meeting on 17 February 2016.</p><p> </p><p>In the absence of guidance from NICE, it is for commissioners to make decisions on whether to fund medicines based on an assessment of the available evidence.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 26414 question first answered 12/02/2016 16:21:56 answering member 4020 label Biography information for George Freeman
tabling member	1540 label Biography information for Greg Mulholland

451516

registered interest
date	09/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effectiveness of local authorities in carrying out their duties under the new commissioning arrangements to ensure that the needs of people living with HIV in their areas are met.
tabling member constituency	Exeter
tabling member printed	Mr Ben Bradshaw
uin	26434
answer	answer is ministerial correction date of answer 11/02/2016 answer text <p>Decisions on funding and access to social care support services for people with HIV are made by local authorities. The Care Act 2014 sets out the legal framework for social care in England, and this applies to all adults with support needs including those living with HIV.</p><p> </p><p>Diagnosed early most people with access to HIV treatment can expect a near normal life expectancy. Public Health England monitors the results of individuals receiving NHS HIV treatment. In 2014, 91% of people attending for care were receiving antiretroviral (ARV) treatment of which 95% were virally suppressed and very unlikely to be infectious to others. The United Kingdom is already ahead in meeting two of the three ambitious UNAIDS 90/90/90 global goals of 90% of people with HIV being diagnosed, 90% on ARV treatment and 90% viral suppression for those on ARV treatment by 2020.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 26137 26151 question first answered 11/02/2016 17:56:25 answering member 3918 label Biography information for Jane Ellison
tabling member	230 label Biography information for Mr Ben Bradshaw

451542

registered interest
date	09/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Procurement
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent discussions he has had with the Care Quality Commission on proposed changes to the contracts of Experts by Experience.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	26642
answer	answer is ministerial correction date of answer 15/02/2016 answer text <p>The Care Quality Commission (CQC) is the independent regulator for health and adult social care. The CQC is responsible for its own staffing requirements, including any decisions on contracts around the supplying of experts by experience for its inspections of providers.</p><p> </p><p>In line with Cabinet Office approvals processes, the Department:</p><p> </p><ul><li>gave approval for the CQC to invite tenders for the Experts by Experience programme; and</li><li>having sought and received clarification of the business case from CQC, approved the business case, to enable the CQC to proceed with finalising new contracts for Experts by Experience.</li></ul> answering member constituency Ipswich answering member printed Ben Gummer question first answered 15/02/2016 09:53:52 answering member 3988 label Biography information for Ben Gummer
tabling member	1439 label Biography information for Norman Lamb

451559

registered interest
date	09/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Mortality Rates
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress NHS England has made on improving cancer survival rates.
tabling member constituency	Lewes
tabling member printed	Maria Caulfield
uin	26491
answer	answer is ministerial correction date of answer 15/02/2016 answer text <p>Cancer survival rates are at a record high and continue to improve. However, we know that we have to strive to be better. The Independent Cancer Taskforce’s report, Achieving World-Class Cancer Outcomes (July 2015), recommends improvements across the cancer pathway, and set a clear ambition for further improvement of survival rates.</p><p> </p><p>NHS England is currently working with partners across the health system to determine how best to take forward the Taskforce’s recommendations and has appointed Cally Palmer CBE as National Cancer Director to lead on implementation, as well as new cancer vanguards to redesign care and patient experience. A new cross-system Cancer Transformation Board has been established to oversee the implementation of the strategy, and this met for the first time on Monday 25 January. There will also be a Cancer Advisory Group, chaired by Sir Harpal Kumar, to oversee and scrutinise the work of the Transformation Board.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 15/02/2016 09:45:26 answering member 3918 label Biography information for Jane Ellison
tabling member	4492 label Biography information for Maria Caulfield

451563

registered interest
date	09/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with the Royal College for Nursing on the connection between cancer drugs and dementia.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	26389
answer	answer is ministerial correction date of answer 15/02/2016 answer text <p>There have been no such discussions.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 15/02/2016 09:38:32 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

451564

registered interest
date	09/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	IVF
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he plans to make the new natural form of IVF treatment available on the NHS.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	26390
answer	answer is ministerial correction date of answer 17/02/2016 answer text <p>It is for clinical commissioning groups to determine the provision of local fertility services based on local need and the best evidence of clinical effectiveness, taking account of National Institute for Health and Care Excellence guidelines. ‘Natural in vitro fertilisation (IVF)’ would be subject to individual clinical decision-making if the patient’s circumstances indicated such an approach was appropriate.</p><p> </p><p>Women considering ‘natural IVF’ should discuss treatment options with their clinician and have regard to the relevant pages of the website of the Human Fertilisation and Embryology Authority:</p><p>http://www.hfea.gov.uk/natural-cycle-ivf.html</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 17/02/2016 13:22:00 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

451565

registered interest
date	09/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Sclerosis: Stem Cells
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he plans to make new stem-cell therapy available on the NHS for patients with multiple sclerosis.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	26391
answer	answer is ministerial correction date of answer 17/02/2016 answer text <p>The Government continues to support research through a range of funding agencies into new treatments for multiple sclerosis. Clinical trials are currently underway to test the potential of stem cell treatments for multiple sclerosis. Before any treatment could be made available on the National Health Service it would have to meet normal standards of safety and effectiveness.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 17/02/2016 07:53:17 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon